WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

List of DDDs for 3 years revision

The DDDs, which will be reviewed at the March 2019 meeting (3 year revision) are listed below.  See also Guidelines: Part III; D Principles for reviewing and changing DDD and Part V; D Requests for changes to DDDs. The deadline for applications for alterations and comments is 1 February 2019.  

 

ATC codeATC level name (INN/generic name)DDDUnitAdm.route
V03AE08ferric citrate6gO
R03DX09mepolizumab3.6mgP
R03DA11doxofylline0.8gO,P
N06BX13idebenone0.9gO
N05BA24bentazepam75mgO
N05AX14iloperidone18mgO
N04BD03safinamide75mgO
N03AX23brivaracetam0.1gO,P
M09AX03ataluren2.8gO
M01AE01ibuprofen1.2gP
L04AC10secukinumab10mgP
L04AA32apremilast60mgO
J04AB05rifapentine0.11gO
J02AC05isavuconazole0.2gO,P
J02AC04posaconazole0.3gP
J01XX11tedizolid0.2gO,P
J01XE03furazidin0.3gO
J01XA04dalbavancin1.53)P
J01DI54ceftolozone and beta-lactamase inhibitor3 2)P
G04BX16tiopronin0.8gO
G03XB51mifepristone, combinations0.21)O
C10AX14alirocumab5.4mgP
C10AX13evolocumab10mgP
B01AX01defibrotide1.75gP
B01AF03edoxaban60mgO
B01AC25cangrelor50mgP
A16AB14sebelipase alfa5mgP
A16AB12elosulfase alfa20mgP
A06AH03naloxegol25mgO
1) Refers to mifepristone
2) Refers to ceftolozane
3) Course dose

Last updated: 2019-02-11